NO20041266L - Piperidinderivater som kan anvendes som CCR5-antagonister - Google Patents

Piperidinderivater som kan anvendes som CCR5-antagonister

Info

Publication number
NO20041266L
NO20041266L NO20041266A NO20041266A NO20041266L NO 20041266 L NO20041266 L NO 20041266L NO 20041266 A NO20041266 A NO 20041266A NO 20041266 A NO20041266 A NO 20041266A NO 20041266 L NO20041266 L NO 20041266L
Authority
NO
Norway
Prior art keywords
piperidine derivatives
ccr5 antagonists
ccr5
antagonists
piperidine
Prior art date
Application number
NO20041266A
Other languages
English (en)
Norwegian (no)
Inventor
Michael W Miller
Anandan Palani
Jack D Scott
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20041266L publication Critical patent/NO20041266L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041266A 2001-08-29 2004-03-26 Piperidinderivater som kan anvendes som CCR5-antagonister NO20041266L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31568301P 2001-08-29 2001-08-29
PCT/US2002/027389 WO2003020716A1 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
NO20041266L true NO20041266L (no) 2004-03-26

Family

ID=23225580

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041266A NO20041266L (no) 2001-08-29 2004-03-26 Piperidinderivater som kan anvendes som CCR5-antagonister

Country Status (24)

Country Link
US (4) US20040010008A1 (es)
EP (1) EP1421075B1 (es)
JP (2) JP4223950B2 (es)
KR (1) KR20040029057A (es)
CN (1) CN1304389C (es)
AR (1) AR036366A1 (es)
AT (1) ATE328879T1 (es)
BR (1) BR0212108A (es)
CA (1) CA2457861A1 (es)
CY (1) CY1105198T1 (es)
DE (1) DE60212146T2 (es)
DK (1) DK1421075T3 (es)
EC (1) ECSP044993A (es)
ES (1) ES2264491T3 (es)
HK (1) HK1061563A1 (es)
HU (1) HUP0402019A3 (es)
IL (1) IL160060A0 (es)
MX (1) MXPA04001886A (es)
NO (1) NO20041266L (es)
PL (1) PL368827A1 (es)
PT (1) PT1421075E (es)
RU (1) RU2004109510A (es)
WO (1) WO2003020716A1 (es)
ZA (1) ZA200401594B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
IL159256A0 (en) 2001-07-02 2004-06-01 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
WO2004035541A1 (en) * 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
ATE520683T1 (de) * 2003-11-03 2011-09-15 Schering Corp Als inhibitoren von chemokinrezeptoren geeignete bipiperidinylderivate
AU2004289690A1 (en) * 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
EP1734966B1 (en) 2004-04-13 2013-07-31 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1844037A1 (en) * 2005-01-20 2007-10-17 Pfizer Limited Chemical compounds
AR055313A1 (es) * 2005-02-23 2007-08-15 Schering Corp Derivados piperidinil piperidina utiles como inhibidores de receptores de quimioquinas. proceso de obtencion y composiciones farmaceuticas
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
BRPI0817935A2 (pt) 2007-10-01 2015-04-07 Hoffmann La Roche Derivados de biarila
MX2010013109A (es) 2008-06-18 2010-12-20 Hoffmann La Roche Nuevos derivados de heteroaril-carboxamida.
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN106029657A (zh) * 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
CA2934132A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
AP2016009303A0 (en) 2013-12-19 2016-06-30 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines
CN107438437B (zh) 2015-04-02 2021-01-01 普罗克斯马根有限责任公司 用于癌症的治疗
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
NZ333513A (en) * 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP1659111A3 (en) * 1999-05-04 2007-05-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
JP2008222722A (ja) 2008-09-25
US7384948B2 (en) 2008-06-10
BR0212108A (pt) 2004-08-24
JP2005502682A (ja) 2005-01-27
WO2003020716A1 (en) 2003-03-13
MXPA04001886A (es) 2004-06-15
ES2264491T3 (es) 2007-01-01
US8034933B2 (en) 2011-10-11
ECSP044993A (es) 2004-04-28
HUP0402019A2 (hu) 2005-02-28
EP1421075B1 (en) 2006-06-07
ATE328879T1 (de) 2006-06-15
US20040010008A1 (en) 2004-01-15
PT1421075E (pt) 2006-10-31
AR036366A1 (es) 2004-09-01
HUP0402019A3 (en) 2009-07-28
US20040092745A1 (en) 2004-05-13
DK1421075T3 (da) 2006-09-18
US7442703B2 (en) 2008-10-28
DE60212146T2 (de) 2007-06-06
KR20040029057A (ko) 2004-04-03
US20040092551A1 (en) 2004-05-13
ZA200401594B (en) 2004-11-24
DE60212146D1 (de) 2006-07-20
IL160060A0 (en) 2004-06-20
HK1061563A1 (en) 2004-09-24
PL368827A1 (en) 2005-04-04
CA2457861A1 (en) 2003-03-13
CY1105198T1 (el) 2010-03-03
JP4223950B2 (ja) 2009-02-12
CN1304389C (zh) 2007-03-14
RU2004109510A (ru) 2005-10-20
EP1421075A1 (en) 2004-05-26
US20080214575A1 (en) 2008-09-04
CN1551877A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
NO20041266L (no) Piperidinderivater som kan anvendes som CCR5-antagonister
NO20015365D0 (no) Piperidinderivater som er anvendbare som CCR5-antagonister
NO20040028L (no) Substituerte anilinske piperidiner som MCH-selektive antagonister
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20015366L (no) Piperazinderivater som er anvendbare som CCR5-antagonister
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
DK1326858T3 (da) Piperidinforbindelser som anti-allergiske midler
NO20053569L (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK1492786T3 (da) Pyridinoylpiperidiner som 5-HT1F-agonister
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20033593L (no) Kinazoliner som MMP-13 inhibitorer
NO20021450L (no) Cykliske aminforbindelser som CCR5-antagonister
NO20021239L (no) Pteridinoner som kinase-inhibitorer
NO20033572D0 (no) Viskoelastiske blandinger
IS7453A (is) Trópan afleiður sem CCR5 stillar
ATE308543T1 (de) Piperidinderivate
NO20023293D0 (no) Piperidin- og piperazinderivater som virker som 5-HT2A- reseptorantagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
NO20034695D0 (no) Nye sammensetninger
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
NO20032315L (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
DE60207399D1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
NO20043119L (no) Triazolokinolinderivater som kan anvendes som adenosinreseptorligander
ATE418542T1 (de) Als ccr5-antagonisten verwendbare aryloxim- piperazine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application